These press releases are intended for business journalists and analysts/investors
Pharmacy Level Recall - Bactroban® Cream (mupirocin calcium 2%) and Bactroban® Nasal Ointment (mupirocin calcium 2%)
Recall of five batches of Bactroban Cream and three batches of Bactroban Nasal Ointment
GSK’s malaria candidate vaccine, MosquirixTM (RTS,S), receives positive opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa
WHO will now assess how the world’s first malaria candidate vaccine might be used alongside other tools to prevent malaria
Zovirax Ophthalmic Ointment (aciclovir 3%) is impacted by an ongoing global supply constraint with no confirmed resupply date in Australia.
Australian campaign focuses on enlarged prostates
GSK Australia and New Zealand have published the third annual responsible business report, outlining key achievements in health, community and environmental sustainability.
GSK Australia has a new immunisation resource for Aboriginal and Torres Strait Islanders this month to encourage families to be proactive when it comes to immunising themselves and their children against preventable diseases.
GSK Australia is a recipient of a grant through of the Federal Government’s Manufacturing Transition Programme worth AUD$1 million. Funding will support GSK’s advanced manufacturing expansion plans at its Boronia site which focus on new product development using innovative “Blow-Fill-Seal” (BFS) technology.
GlaxoSmithKline (GSK) Australia reported to the Australian Securities and Investment Commission (ASIC) sales revenue of $906m in 2014 for its continuing operations and a profit before tax of $22m.
We are one of the world’s largest science-led pharmaceutical and healthcare companies. Each year we research, manufacture and sell innovative medicines, vaccines and healthcare products for millions of people across the world, helping them to do more, feel better and live longer.